Gilead Sciences ( NASDAQ: GILD ) shares traded in the green on Tuesday, making it the seventh consecutive days of gains. The stock closed up 0.04% at $76.
99. GILD stock fell about 0.06% in the last 12 months.
YTD, the stock is trading down about 5.1%, compared to the broader S&P 500 market which is up 17.81%.
Looking at Seeking Alpha's Quant Ratings, this company has a Hold rating with a score of 3.27 out of 5. When it comes to Wall Street analysis, 14 out of 30 analysts recommend a Hold, 8 recommend a Strong Buy, 7 recommend a Buy and 1 recommends a Strong Sell.
Gilead this month announced that the FDA approved its liver disease therapy Livdelzi (seladelpar), added with its recent buyout of CymaBay Therapeutics. It also raised its 2024 non-GAAP EPS guidance following Q2 results that beat on both lines. Seeking Alpha analysts have a Buy rating on the company.
More on Gilead Sciences Gilead Sciences, Inc. (GILD) Q2 2024 Earnings Call Transcript Gilead Sciences, Inc. 2024 Q2 - Results - Earnings Call Presentation Gilead's New Anti-Obesity Drug: The Real Reason Behind The 25% Stock Surge? Gilead wins FDA nod for liver disease drug Gilead exits J&J royalty deal for liver drug ahead of potential FDA nod.
